Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02470091 · ClinicalTrials.gov registry record · Phase 2
Denosumab in Treating Patients With Recurrent or Refractory Osteosarcoma
A Phase 2 study, sponsored by Children's Oncology Group.
- Completed
- Registry status
- Phase 2
- Development phase
- 56
- Enrollment target
NCT02470091 is a Phase 2 study that has completed, run by Children's Oncology Group. The registered enrollment target is 56 participants.
The verdict
NCT02470091, a Phase 2 study, has completed, sponsored by Children's Oncology Group.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 56 participants
- Enrollment target
Study Summary
This phase II trial studies how well denosumab works in treating patients with osteosarcoma that has come back (recurrent) or does not respond to treatment (refractory). Immunotherapy with monoclonal antibodies, such as denosumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.
Interventions
- OTHER Laboratory Biomarker Analysis
- OTHER Pharmacological Study
- BIOLOGICAL Denosumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 56 participants |
| Start Date | 2015-11-21 |
| Est. Completion | 2023-12-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02470091
The ClinicalTrials.gov registry entry for NCT02470091 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 56 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Children's Oncology Group, which has 342 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Laboratory Biomarker Analysis is the first listed.
NCT02470091 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02470091 about?
NCT02470091 is a clinical study titled "Denosumab in Treating Patients With Recurrent or Refractory Osteosarcoma". This phase II trial studies how well denosumab works in treating patients with osteosarcoma that has come back (recurrent) or does not respond to treatment (refractory). Immunotherapy with monoclonal antibodies, such as denosumab, may help the body's immune system attack the cancer, and may interfer...
What is the current status of trial NCT02470091?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 56 participants. The study started on 2015-11-21. Estimated completion is 2023-12-31.
What interventions are being tested in trial NCT02470091?
The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), Pharmacological Study (OTHER), Denosumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT02470091?
This trial is sponsored by Children's Oncology Group, which has 342 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.